Alnylam Pharmaceuticals (ALNY) Non Operating Interest Expenses (2020 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Non Operating Interest Expenses (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 582,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 82.05 Mn |
| Mar 31, 2026 | 69.29 Mn |
| Dec 31, 2025 | 65.40 Mn |
| Sep 30, 2025 | 44.40 Mn |
| Jun 30, 2025 | 61.46 Mn |
| Mar 31, 2025 | 58.31 Mn |
| Dec 31, 2024 | 38.97 Mn |
| Sep 30, 2024 | 34.38 Mn |
| Jun 30, 2024 | 33.26 Mn |
| Mar 31, 2024 | 35.25 Mn |
| Dec 31, 2023 | 31.34 Mn |
| Sep 30, 2023 | 30.89 Mn |
| Jun 30, 2023 | 30.04 Mn |
| Mar 31, 2023 | 28.96 Mn |
| Dec 31, 2022 | 29.91 Mn |
| Sep 30, 2022 | 41.08 Mn |
| Jun 30, 2022 | 42.61 Mn |
| Mar 31, 2022 | 42.36 Mn |
| Dec 31, 2021 | 36.82 Mn |
| Sep 30, 2021 | 40.27 Mn |